Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Defining the limits of immunotherapy in early small-cell lung cancer

13

Mar 2026

Defining the limits of immunotherapy in early small-cell lung cancer

Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC) according to the results of an international clinical trial, NRG-LU005, led by NRG Oncology in collaboration with the Alliance for Clinical Trials in Oncology. The results are published in the Journal of Clinical Oncology.

NUS uncovers NuSAP’s role in centriole stability

12

Mar 2026

NUS uncovers NuSAP’s role in centriole stability

Biologists at the National University of Singapore (NUS) have uncovered how the protein NuSAP safeguards tiny structures inside cells called centrioles, revealing a mechanism linked to developmental disorders such as microcephaly and mosaic variegated aneuploidy (MVA) syndrome.

Swapping red meat for plant-based meat rapidly lowers a key heart risk metabolite, trial finds

12

Mar 2026

Swapping red meat for plant-based meat rapidly lowers a key heart risk metabolite, trial finds

A randomized crossover trial found that replacing red meat patties with processed plant-based meat alternatives for six days significantly lowered circulating trimethylamine N-oxide (TMAO), a gut-derived metabolite linked to cardiovascular risk. The plant-based phase also produced modest reductions in cholesterol markers but slightly increased weight and NT-proBNP, possibly due to higher sodium intake.

Study reveals racial differences in early Alzheimer's brain changes

12

Mar 2026

Study reveals racial differences in early Alzheimer's brain changes

A team of researchers at the USC Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI) at the Keck School of Medicine of USC has identified important differences in how early Alzheimer's disease-related brain changes appear across racial and ethnic groups, underscoring the need for more inclusive approaches to studying and diagnosing the disease.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.